Safety and efcacy of restarting immune checkpoint inhibitors in non‑small cell lung cancer patients following immune‑related adverse events: a systematic review and meta‑analysis

Kexin Tan; Aolin Wang; Yumin Zheng; Shuo Wang; Chao Wang; Jia Li; Xingyu Lu; Huijing Dong; Jiabin Zheng; Huijuan Cui

Ayuda

Safety and efcacy of restarting immune checkpoint inhibitors in non‑small cell lung cancer patients following immune‑related adverse events: a systematic review and meta‑analysis

Kexin Tan ^[1] ; Aolin Wang ^[1] ; Yumin Zheng ^[1] ; Shuo Wang ^[2] ; Chao Wang ^[2] ; Jia Li ^[1] ; Xingyu Lu ^[1] ; Huijing Dong ^[1] ; Jiabin Zheng ^[2] ; Huijuan Cui ^[2]
1. [1] Beijing University of Chinese Medicine
  
  Beijing University of Chinese Medicine
  
  China
2. [2] China-Japan Friendship Hospital
  
  China-Japan Friendship Hospital
  
  China
Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 27, Nº. 1, 2025, págs. 196-203
Idioma: inglés
Texto completo no disponible (Saber más ...)
Resumen
- Objective This meta-analysis aims to evaluate the safety and efcacy of restarting immune checkpoint inhibitors (ICIs) in patients with non-small cell lung cancer (NSCLC) after experiencing immune-related adverse events (irAEs).
  
  Methods A comprehensive search of PubMed, Web of Science, Embase, and the Cochrane Library was conducted to identify studies investigating the safety and efcacy of restarting ICIs in NSCLC patients after irAEs. Outcome measures, including objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) after ICI restarting, were extracted. Meta-analysis was performed using the R meta-package.
  
  Results Four studies involving a total of 326 subjects were included, comprising 137 patients who restarted ICI treatment after irAEs and 189 patients who did not restart ICI treatment. The results revealed that ICI restarting was associated with an increased ORR (OR=2.36, 95% CI 1.49–3.84), prolonged PFS (HR=0.60, 95% CI 0.42–0.86), and prolonged OS (HR=0.65, 95% CI 0.43–0.99) compared to non-restarting. The incidence of irAEs after ICI restarting was 45% (95% CI 0.27–0.63).
  
  Conclusion Restarting ICI treatment after discontinuation due to previous irAEs appears to be a reasonable option for NSCLC patients. However, a comprehensive assessment of the potential benefts and risks to individual patients is crucial, and close monitoring of irAEs is warranted.